| Autor: |
A M El Badri, Salma, Salawu, Abdulazeez, Brown, Janet E |
| Zdroj: |
Current Osteoporosis Reports; Dec2019, Vol. 17 Issue 6, p527-537, 11p |
| Abstrakt: |
Purpose of Review: The improvement in prostate cancer survival over time, even in those with advanced disease, has led to an increasing recognition of the impact of prostate cancer and its treatment on bone health. Cancer treatment–induced bone loss (CTIBL) is a well-recognized entity but greater awareness of the risks associated with CTIBL and its treatment is required. Recent Findings: The principal culprit in causing CTIBL is hormonal ablation induced by prostate cancer treatment, including several new agents which have been developed in recent years which significantly improve survival, but may cause CTIBL. This review discusses the impact of prostate cancer and its treatment on bone health, including published evidence on the underlying pathophysiology, assessment of bone health, and strategies for prevention and treatment. Summary: It is important to recognize the potential cumulative impact of systemic prostate cancer treatments on bone health. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink